Kai Kappert Selected Research

Telmisartan (Micardis)

1/2017	AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in mice.
8/2012	Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
10/2011	High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kai Kappert Research Topics

Disease

11	Insulin Resistance 01/2024 - 01/2008
10	Atherosclerosis 01/2017 - 02/2004
8	Obesity 01/2024 - 01/2008
8	COVID-19 01/2022 - 01/2020
7	Inflammation (Inflammations) 01/2022 - 01/2008
7	Neointima 01/2016 - 12/2004
5	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 02/2005
5	Neoplasms (Cancer) 07/2019 - 06/2007
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2013 - 07/2011
3	Infections 05/2024 - 10/2021
3	Hemolysis 04/2022 - 01/2018
3	Periodontitis 10/2021 - 01/2016
3	Heart Failure 07/2017 - 01/2008
3	Myocardial Infarction 07/2013 - 07/2009
3	Hypoxia (Hypoxemia) 07/2011 - 04/2011
3	Atherosclerotic Plaque (Atheroma) 01/2011 - 04/2010
3	Vascular Diseases (Vascular Disease) 12/2006 - 02/2004
2	Bacterial Infections (Bacterial Infection) 05/2024 - 10/2021
2	Sepsis (Septicemia) 05/2024 - 10/2022
2	Metabolic Diseases (Metabolic Disease) 01/2024 - 03/2016
2	Fibrosis (Cirrhosis) 01/2022 - 07/2013
2	Virus Diseases (Viral Diseases) 10/2021 - 07/2017
2	Disease Progression 01/2020 - 01/2008
2	Hyperlipidemias (Hyperlipidemia) 01/2020 - 12/2006
2	Pulmonary Hypertension 02/2019 - 04/2011
2	Hypertension (High Blood Pressure) 01/2018 - 09/2010
2	Body Weight (Weight, Body) 03/2016 - 07/2013
2	Thrombosis (Thrombus) 01/2016 - 06/2011
2	Coronary Artery Disease (Coronary Atherosclerosis) 06/2013 - 09/2010
2	Vascular System Injuries 02/2012 - 06/2011
1	Clinical Deterioration 05/2024
1	Stroke (Strokes) 01/2023
1	Ischemic Stroke 01/2023
1	Cardiomegaly (Heart Hypertrophy) 01/2022
1	Pathologic Processes 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 11/2021
1	Hyperplasia 11/2021
1	Activated Protein C Resistance (APC Resistance) 01/2021
1	Renal Insufficiency (Renal Failure) 01/2021
1	Iron Deficiencies 12/2020

Drug/Important Bio-Agent (IBA)

7	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 09/2010
6	Insulin (Novolin)FDA Link 01/2024 - 01/2008
5	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2018
5	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 01/2024 - 02/2005
5	Proteins (Proteins, Gene)FDA Link 12/2021 - 06/2007
5	LigandsIBA 01/2016 - 12/2004
4	CollagenIBA 10/2021 - 07/2013
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2019 - 10/2011
4	FurinIBA 02/2013 - 03/2010
4	Platelet-Derived Growth FactorIBA 06/2011 - 02/2004
3	Tyrosine (L-Tyrosine)FDA Link 01/2024 - 04/2011
3	Messenger RNA (mRNA)IBA 10/2022 - 01/2018
3	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2020
3	Protein Tyrosine PhosphatasesIBA 01/2020 - 04/2011
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020 - 12/2006
3	Telmisartan (Micardis)FDA Link 01/2017 - 10/2011
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 03/2016 - 04/2011
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 05/2024 - 01/2021
2	PotassiumIBA 04/2022 - 01/2020
2	Blood Proteins (Serum Proteins)IBA 12/2021 - 07/2019
2	Small Interfering RNA (siRNA)IBA 01/2020 - 04/2011
2	InterferonsIBA 01/2020 - 07/2017
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 12/2006
2	ElementsIBA 01/2017 - 07/2009
2	oxidized low density lipoproteinIBA 01/2017 - 10/2010
2	Pioglitazone (Actos)FDA Link 04/2016 - 01/2008
2	Transcription Factors (Transcription Factor)IBA 01/2016 - 07/2009
2	Insulin ReceptorIBA 04/2015 - 07/2013
2	Matrix Metalloproteinases (MMPs)IBA 01/2013 - 07/2009
2	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 01/2013 - 01/2011
2	Type 1 Angiotensin ReceptorIBA 10/2011 - 09/2010
2	IntegrinsIBA 03/2010 - 07/2009
2	Ritonavir (Norvir)FDA Link 12/2006 - 02/2004
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2024
1	CannabinoidsIBA 12/2022
1	GlycopeptidesIBA 01/2022
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022
1	SaltsIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Desoxycorticosterone Acetate (DOCA)FDA Link 01/2022
1	ProteomeIBA 12/2021
1	Neutralizing AntibodiesIBA 10/2021
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 10/2021
1	ProcalcitoninIBA 10/2021
1	Cell Adhesion MoleculesIBA 01/2021
1	AntithrombinsIBA 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2021
1	Factor V (Coagulation Factor V)IBA 01/2021
1	Protein CIBA 01/2021
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2021
1	PlasminogenIBA 01/2021
1	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 01/2021
1	BNT162 VaccineIBA 01/2021
1	Protein SIBA 01/2021
1	VaccinesIBA 01/2021
1	Thromboplastin (Tissue Factor)IBA 01/2021
1	Ferritins (Ferritin)IBA 12/2020

Therapy/Procedure

7	Therapeutics 01/2023 - 12/2004
2	Stents 01/2016 - 06/2011
1	Thrombectomy 01/2023